Monroe facility FDA reinspection delay
Remediation completed but FDA reinspection pending; delay could impact injectable commercialization timeline.
high · management_commentary
Glenmark Pharmaceuticals Limited — Q4 FY24
Glenmark's Q4 FY24 consolidated revenue grew 2.1% YoY to INR 3,063 crore, with India formulation up 12.9% and ROW up 10%, but North America declined 12.4% due to lack of launches.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Elevated legal settlement cash outflows
Cash payout of ~INR 300 crore in FY25 for DOJ and Zetia settlements, impacting free cash flow.
medium · analyst_questionNorth America revenue decline and lack of launches
North America revenue fell 12.4% YoY; recovery depends on generic Flovent approval and scale-up of recent launches.
high · data_observationIGI R&D spend remains high at $50 million
Despite earlier guidance to reduce Ichnos spend, FY25 IGI cash R&D is $50 million, pressuring profitability.
medium · analyst_question